|Bid||88.88 x 800|
|Ask||103.61 x 1000|
|Day's range||96.49 - 97.51|
|52-week range||67.51 - 97.51|
|PE ratio (TTM)||76.49|
|Earnings date||31 Oct 2018 - 5 Nov 2018|
|Forward dividend & yield||0.28 (0.29%)|
|1y target est||90.62|
PerkinElmer is working to ease the drug discovery process for pharmaceutical companies with its suite of research, detection and diagnostics tools.
This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about Return on Equity using a real-life example. PerkinElmer Inc’sRead More...
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In August, nine analysts are covering Varian Medical Systems (VAR) stock. Three of them have given the stock a “strong buy” rating, three have given it a “hold,” and three have given it a “sell.” The mean rating for VAR stock is 2.67 with a target price of $122. That implies an upside potential of 9.1% over its closing price of $111.83 on August 20.
NEW YORK, Aug. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cognex ...
The Nasdaq led gains in stocks today, and Apple reached a new all-time high. The stock is extended past a pair of recent new buy points.
Apple leads five top stocks to watch that are in or near buy range and showing relative strength. CSX, Ross Stores, Zoetis and PerkinElmer are also triggering a bullish technical signal.
The canny investor should always be looking for top stocks with accelerating sales growth. This key bullish trait is shared by Apple stock, PerkinElmer, SVB Financial and Square.
Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.
PerkinElmer (PKI) delivered earnings and revenue surprises of 5.81% and 1.38%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had profit of 57 cents per share. Earnings, adjusted for one-time gains and costs, were 91 cents per share. The results surpassed Wall Street expectations. ...
PerkinElmer (PKI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
athenahealth's (ATHN) core Business Services unit is likely to drive growth in Q2; the company's focus on cloud-based services is encouraging.
Strong performance in the Diagnostics Segment is likely to drive PerkinElmer's (PKI) Q2 results. The segment fortifies the company's market position in terms of exclusiveness of services.
PerkinElmer Inc (NYSE:PKI), a life sciences company based in United States, saw significant share price volatility over the past couple of months on the NYSE, rising to the highs ofRead More...
Solid prospects in PerkinElmer's (PKI) DAS segment are the key drivers of Q1. Strength in life sciences end markets, informatics profile and OneSource have given the top line a boost.
On a per-share basis, the Waltham, Massachusetts-based company said it had profit of 23 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 63 cents per share. The results topped ...
STERIS' (STE) string of six buyouts in fiscal 2018 keeps us upbeat about the stock. The same is expected to strengthen its Healthcare Specialty Services and Applied Sterilization Technologies arms.
Davita's kidney care unit is gaining prominence worldwide. However, the company is grappling with labor-union woes in California and Ohio.